KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection.
Check out the visual abstract created by Natalia Nombera
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies.
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection.
Check out the visual abstract created by Natalia Nombera
Las guías KDIGO 2025 están aquí. El manejo de la nefropatía por IgA (NIgA) está evolucionando con herramientas de estratificación de riesgo más precisas, nuevas terapias y un enfoque más sólido en la protección renal a lo largo de la vida.
Revisa el resumen visual creado por Natalia Nombera
Hard to summarize all ADPKD guidelines in just 10 posts, but here it is!
The KDIGO ADPKD guideline is a result of a decade of global collaboration between physicians, researchers, advocates, and patients. 240 pages summarized in only 2 pictures, made by Cristina Popa.
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
Check out the TOP 10 takeaways from KDIGO - CKD guidelines on evaluation of people with or at risk of CKD by NSMC Intern Stephanie Torres
This update was too big for just one slide! Michael Turk produced two Visual Primers to help you understand the 2021 GN changes at-a-glance.